Melanotan I
Afamelanotide
Description
Melanotan I is a synthetic analog of the naturally occurring alpha-melanocyte-stimulating hormone (α-MSH), primarily investigated for its role in stimulating melanin production and skin pigmentation. It is also being explored for various therapeutic applications beyond tanning.
Overview
Melanotan I, also known as afamelanotide, is a synthetic peptide that mimics the effects of α-MSH, a natural hormone involved in pigmentation. Its primary research application centers on its ability to stimulate melanogenesis, leading to increased skin tanning and reduced susceptibility to sunburn. Early clinical trials have demonstrated its efficacy in these areas, particularly when combined with UV exposure. Beyond its role in tanning, Melanotan I has shown promise in addressing various dermatological conditions. Studies have explored its potential in treating xeroderma pigmentosum, a genetic disorder characterized by extreme UV sensitivity, and polymorphic light eruption, a condition causing rash upon sun exposure. Additionally, research indicates potential benefits in managing erythropoietic protoporphyria, a painful photosensitivity disorder, by improving pain levels and quality of life for affected individuals. Interestingly, Melanotan I has also been investigated for its potential to improve mood and outlook, particularly in patients undergoing photodynamic therapy. Furthermore, preliminary studies suggest it may have a role in treating acne vulgaris, showing reductions in inflammatory lesions. While research is ongoing, these diverse applications highlight the peptide's multifaceted therapeutic potential.
Mechanism of Action
Melanotan I functions as an agonist at melanocortin receptors, primarily targeting MC1R. This binding action initiates increased production of melanin, the pigment responsible for skin, hair, and eye color. It is structurally similar to α-MSH but exhibits enhanced potency and stability.
Benefits
- •Stimulates melanin production
- •Enhances skin tanning
- •Reduces sunburn occurrence
- •May improve mood and outlook
- •Potential treatment for certain skin conditions
Dosing Notes
Typical daily dosages for skin tanning purposes range from 0.25 mg to 2 mg, administered subcutaneously. It is generally recommended to begin with the lowest effective dose and gradually increase until the desired tanning effect is achieved. In clinical studies for skin conditions, dosages of 0.08 mg/kg to 0.16 mg/kg per day were used in Phase I trials, with Phase II and III European studies utilizing 16 mg implants for durations up to four months.
Reported Side Effects
- •Nausea
- •Transient facial flushing
- •Mild and short-term fatigue
Safety Notes
Melanotan I is considered a research chemical and is not approved for general use. While clinical study data generally indicates a favorable safety profile with mild side effects, there have been case reports linking its use to the development of eruptive melanocytic nevi (moles) and changes in existing moles. One reported case also described melanotan-induced priapism. Therefore, its administration should be restricted to research settings under strict medical supervision.